NDC codes

FDA NDC Directory
Product NDC (as listed)85006-2908Labeler and product segments. Claims need a package NDC.
Product NDC at billing width85006-2908Add the package segment from the table below.
Package NDCs as listed with the FDA, and the 11-digit 5-4-2 form used on claims. The highlighted digit is the added leading zero.
Package NDC11-digit (billing)PackageCopy
85006-2908-185006290801.05 mL in 1 VIAL, SINGLE-DOSE (85006-2908-1)Marketed from Oct 24, 2025

How the 11-digit form is made: The package segment has 1 digit, so one leading zero is added to it (5-4-1 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules

Product information

Brand name (proprietary)
Ahzantive
Generic name (nonproprietary)
aflibercept-mrbb
Active ingredients
Aflibercept-mrbb — 40 mg/mL
Dosage form
Injection, Solution
Route
Intravitreal
Labeler
Valorum Biologics, LLCNDC labeler code 85006
Product type
Prescription drug
Marketing category
BLA — Biologics License ApplicationApplication BLA 761378
Marketing start
Listing expires
Other FDA classes
Vascular Endothelial Growth Factor Inhibitors (Mechanism)
Identifiers
Product ID 85006-2908_42277606-719f-1fd3-e063-6394a90ad9d6SPL ID 42277606-719f-1fd3-e063-6394a90ad9d6SPL set ID 289e4b90-f741-c0f6-e063-6394a90a2068RxCUI 2706533, 2706541UNII 15C2VL427D
Pharmacologic class
Vascular Endothelial Growth Factor Inhibitor

Billing references

What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.

HCPCS codeNo match

No drug-specific HCPCS code in Med-Code's directory for this product. The directory is curated and not complete — check the current CMS HCPCS file before billing.

NDC on a medical claim

N485006290801 followed by a unit qualifier and the quantity

Package 85006-2908-01. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier

Product label

Current FDA label (SPL), effective .

Indications (excerpt from the label)

These highlights do not include all the information needed to use AHZANTIVE safely and effectively. See full prescribing information for AHZANTIVE. Initial U.S. Approval: 2024 1 INDICATIONS AND USAGE AHZANTIVE is indicated for the treatment of: 1.1 Neovascular (Wet) Age-Related Macular Degeneration (AMD) 1.2 Macular Edema Following Retinal Vein Occlusion (RVO) 1.3 Diabetic Macular Edema (DME) 1.4 Diabetic Retinopathy (DR) AHZANTIVE is a vascular endothelial growth factor (VEGF) inhibitor indicated for the treatment of patients with: Neovascular (Wet) Age-Related Macular Degeneration (AMD) (1.1) Macular Edema Following Retinal Vein Occlusion (RVO) (1.2) Diabetic Macular Edema (DME) (1.3) Diab…

Excerpt only. Read the full label for complete information.

Full label on DailyMed (opens in a new tab)

About NDC 85006-2908

What is NDC 85006-2908?
85006-2908 is the product NDC for Ahzantive (aflibercept-mrbb), Aflibercept-mrbb 40 mg/mL injection, solution, listed with the FDA by Valorum Biologics, LLC. It has 1 package NDC, shown above in 10- and 11-digit form.
What drug is associated with this NDC?
Ahzantive (Aflibercept-mrbb).
What is the active ingredient?
Aflibercept-mrbb.
Who is the labeler?
Valorum Biologics, LLC, NDC labeler code 85006. The labeler is the company responsible for the label; it may be the manufacturer, a repackager or a distributor.
What other NDCs exist for Ahzantive?
None: this is the only finished product listed under this name.
Is there a related HCPCS / J-code?
Not in Med-Code's curated HCPCS directory. See Billing references above.

Free account

Keep searching with a free account

You’ve used your 3 free searches for this session. Log in or create a free Med-Code account to keep looking up NDCs, J-codes and drugs.

Create a free accountLog in